Genesis Therapeutics
James (Korrawat) Pruegsanusak has a diverse work experience:
- From June 2020 to present, they work as an ML Research Engineer at Genesis Therapeutics.
- From September 2015 to May 2020, James worked as a Teaching Assistant at Massachusetts Institute of Technology (MIT). James (Korrawat) supported Prof. Fadel Adib in the Mobile and Sensor Computing course and taught Intro to EECS via Communications Networks.
- From June 2019 to December 2019, they interned as a Software Engineering Intern at Cambridge Mobile Telematics.
- From September 2016 to June 2019, James worked as an Undergraduate Researcher at MIT Computer Science and Artificial Intelligence Laboratory (CSAIL).
- In May 2018, they were a Software Developer Intern at Jane Street.
- In June 2017, they interned as a Software Engineering Intern at VIA Technologies, Inc.
James (Korrawat) Pruegsanusak pursued their education with a focus on computer science and electrical engineering. James (Korrawat) began their educational journey at Triam Udom Suksa School, where they completed their high school education from 2011 to 2014. Following this, they attended Phillips Exeter Academy for a year in 2014-2015, also for high school. James then went on to attend the Massachusetts Institute of Technology (MIT) from 2015 to 2019, where they earned their Bachelor's degree in Electrical Engineering and Computer Science. James (Korrawat) furthered their education at MIT, completing their Master of Engineering (MEng) degree in Computer Science from 2019 to 2020.
Genesis Therapeutics
3 followers
Genesis Therapeutics is an innovative biotechnology company engaging its proprietary molecular AI technology to transform clinical outcomes for patients. The company was founded in 2019 out of Stanford University by Evan Feinberg Ph.D., co-founded by Ben Sklaroff, and backed by Vijay Pande, Ph.D. In addition, Peppi Prasit, Ph.D. leads the Scientific Advisory Board and Leonard Bell, M.D., serves as Chair of the Board of Directors. Its team of technology trailblazers and proven drug developers are driving the discovery and development of novel small molecule drugs to treat patients suffering with severe and debilitating diseases. The company expects to develop drug candidates both internally and selectively in partnership with biopharmaceutical companies.